A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic GPNMB Over-Expressing Triple-Negative Breast Cancer (The METRIC Study)
Brief description of study
The main goal of this randomized pivotal trial is to evaluate the anti-cancer activity of CDX-011 in metastatic, glycoprotein NMB over-expressing, triple-negative breast cancer by characterizing the safety, obtain pharmacokinetic parameters and assess whether treatment with this agent is associated with improvement in quality of life.
Clinical Study Identifier: S14-00306
ClinicalTrials.gov Identifier: NCTS14-00306
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
